RAPT Therapeutics(US:RAPT) Newsfilter·2024-12-23 12:00Core Insights - RAPT Therapeutics has entered into an exclusive licensing agreement with Jemincare for the development and commercialization of RPT904, a novel anti-IgE monoclonal antibody, with worldwide rights excluding China [2][3] - Jemincare will receive a $35 million upfront payment, potential milestone payments up to $672.5 million, and royalties on future sales of RPT904 outside its territory [2][3] - RPT904 is being developed as a potentially improved treatment option for food allergies, targeting the same epitope as omalizumab but with an extended half-life [3][9] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on immunology and developing therapies for inflammatory diseases with significant unmet needs [10] - Jemincare, a leading pharmaceutical company in China, specializes in the development and commercialization of therapeutics across various fields including oncology and respiratory diseases [11] Clinical Development - Jemincare has completed a Phase 1 study of JYB1904, demonstrating good safety and tolerability, with a median half-life more than twice that of omalizumab [4] - Jemincare is currently conducting two Phase 2 trials for JYB1904 in asthma and chronic spontaneous urticaria, with topline data expected in 2025 and 2026 respectively [5] - RAPT plans to initiate a Phase 2b clinical trial of RPT904 in food allergy in the second half of 2025 [3][8]